

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10569583	
	Filing Date		2006-02-23	
	First Named Inventor	Neil Gallagher		
	Art Unit	1654		
	Examiner Name	Julie Ha		
Attorney Docket Number		101213-1P US		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
1						

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
1						

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
1								<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ts

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

1	BOISSIER, S. et al., Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices, Cancer Res, 1997, 3890-3894, 57(18).	<input type="checkbox"/>
2	FOURNIER, P. et al., Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats, Cancer Res, 2002, 6538-6544, 62(22).	<input type="checkbox"/>
3	FROMIGUE, O. et al., Bisphosphonates induce breast cancer cell death in vitro, J Bone Miner Res, 2000, 2211-2221, 15(11).	<input type="checkbox"/>
4	HIRAGA, T. et al., The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases, Cancer Res, 2001, 4418-4424, 61(11).	<input type="checkbox"/>
5	JAGDEV S.P. et al., The bisphosphonate, zoledronic acid, induces aptosis of breast cancer cells: evidence of synergy with paclitaxel, Br J Cancer, 2001, 1126-1134, 84(8).	<input type="checkbox"/>
6	PADALECKI, S.S. et al., Actions of bisphosphonates in animal models of breast cancer, Breast Cancer Res, 2002, 35-41, 4(1).	<input type="checkbox"/>
7	VAN DER PLUIJM, G. et al., Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro, J Clin Invest, 1996, 698-705, 98(3).	<input type="checkbox"/>
8	STEARNS, ME et al., Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice, Clin Exp Metastasis, 1998; 693-702; 16(8).	<input type="checkbox"/>
9	VIRTANEN, S. S. et al, Alendronate Inhibits Invasion of PC-3 Prostate Cancer Cells by Affecting the Mevalonate Pathway, Cancer Res, 2002, 2708-2714, 62(9).	<input type="checkbox"/>
10	YONEDA, T. et al., Actions of Bisphosphonate on Bone Metastasis in Animal Models of Breast Carcinoma, Cancer (Supplement), 2000, 2979-2988, 88(12).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.